These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 10555959)
21. Conserved cholecystokinin receptor transmembrane domain IV amino acids confer peptide affinity. Ren Y; Bläker M; Seshadri L; McBride EW; Beinborn M; Kopin AS J Mol Neurosci; 2003 Apr; 20(2):115-24. PubMed ID: 12794305 [TBL] [Abstract][Full Text] [Related]
22. Conformationally constrained CCK8 analogues obtained from a rationally designed peptide library as ligands for cholecystokinin type B receptor. De Luca S; Saviano M; Della Moglie R; Digilio G; Bracco C; Aloj L; Tarallo L; Pedone C; Morelli G ChemMedChem; 2006 Sep; 1(9):997-1006. PubMed ID: 16915602 [TBL] [Abstract][Full Text] [Related]
23. Direct identification of a distinct site of interaction between the carboxyl-terminal residue of cholecystokinin and the type A cholecystokinin receptor using photoaffinity labeling. Ji Z; Hadac EM; Henne RM; Patel SA; Lybrand TP; Miller LJ J Biol Chem; 1997 Sep; 272(39):24393-401. PubMed ID: 9305898 [TBL] [Abstract][Full Text] [Related]
24. Role of the extracellular domains of the cholecystokinin receptor in agonist binding. Silvente-Poirot S; Escrieut C; Wank SA Mol Pharmacol; 1998 Aug; 54(2):364-71. PubMed ID: 9687578 [TBL] [Abstract][Full Text] [Related]
25. Cholecystokinin receptor characterization and cholecystokinin-A receptor messenger RNA expression in transgenic mouse pancreatic carcinomas and dysplastic pancreas. Povoski SP; Zhou W; Longnecker DS; Bell RH Oncol Res; 1994; 6(9):411-7. PubMed ID: 7703527 [TBL] [Abstract][Full Text] [Related]
26. Refinement of the structure of the ligand-occupied cholecystokinin receptor using a photolabile amino-terminal probe. Ding XQ; Dolu V; Hadac EM; Holicky EL; Pinon DI; Lybrand TP; Miller LJ J Biol Chem; 2001 Feb; 276(6):4236-44. PubMed ID: 11050076 [TBL] [Abstract][Full Text] [Related]
27. Direct identification of a second distinct site of contact between cholecystokinin and its receptor. Hadac EM; Pinon DI; Ji Z; Holicky EL; Henne RM; Lybrand TP; Miller LJ J Biol Chem; 1998 May; 273(21):12988-93. PubMed ID: 9582333 [TBL] [Abstract][Full Text] [Related]
28. Characterization of cholecystokinin receptors and messenger RNA expression in rat pancreas: evidence for expression of cholecystokinin-A receptors but not cholecystokinin-B (gastrin) receptors. Zhou W; Povoski SP; Bell RH J Surg Res; 1995 Mar; 58(3):281-9. PubMed ID: 7533864 [TBL] [Abstract][Full Text] [Related]
29. Natural and synthetic CCK-58. Novel reagents for studying cholecystokinin physiology. Reeve JR; Eysselein VE; Ho FJ; Chew P; Vigna SR; Liddle RA; Evans C Ann N Y Acad Sci; 1994 Mar; 713():11-21. PubMed ID: 7514372 [TBL] [Abstract][Full Text] [Related]
30. Molecular basis of agonist binding to the type A cholecystokinin receptor. Miller LJ; Lybrand TP Pharmacol Toxicol; 2002 Dec; 91(6):282-5. PubMed ID: 12688369 [TBL] [Abstract][Full Text] [Related]
31. Models for the A- and B-receptor-bound conformations of CCK-8. Nikiforovich GV; Hruby VJ Biochem Biophys Res Commun; 1993 Jul; 194(1):9-16. PubMed ID: 8333874 [TBL] [Abstract][Full Text] [Related]
32. Conformational and molecular modeling studies of beta-cyclodextrin-heptagastrin and the third extracellular loop of the cholecystokinin 2 receptor. Giragossian C; Schaschke N; Moroder L; Mierke DF Biochemistry; 2004 Mar; 43(10):2724-31. PubMed ID: 15005607 [TBL] [Abstract][Full Text] [Related]
33. The use of topographical constraints in receptor mapping: investigation of the topographical requirements of the tryptophan 30 residue for receptor binding of Asp-Tyr-D-Phe-Gly-Trp-(N-Me)Nle-Asp-Phe-NH2 (SNF 9007), a cholecystokinin (26-33) analogue that binds to both CCK-B and delta-opioid receptors. Boteju LW; Nikiforovich GV; Haskell-Luevano C; Fang SN; Zalewska T; Stropova D; Yamamura HI; Hruby VJ J Med Chem; 1996 Sep; 39(20):4120-4. PubMed ID: 8831778 [TBL] [Abstract][Full Text] [Related]
34. Essential role of extracellular charged residues of the human CCK(1) receptor for interactions with SR 146131, SR 27897 and CCK-8S. Gouldson P; Legoux P; Carillon C; Dumont X; Le Fur G; Ferrara P; Shire D Eur J Pharmacol; 2000 Feb; 389(2-3):115-24. PubMed ID: 10688974 [TBL] [Abstract][Full Text] [Related]
35. Measurement of intermolecular distances for the natural agonist Peptide docked at the cholecystokinin receptor expressed in situ using fluorescence resonance energy transfer. Harikumar KG; Pinon DI; Wessels WS; Dawson ES; Lybrand TP; Prendergast FG; Miller LJ Mol Pharmacol; 2004 Jan; 65(1):28-35. PubMed ID: 14722234 [TBL] [Abstract][Full Text] [Related]
36. Arginine 336 and asparagine 333 of the human cholecystokinin-A receptor binding site interact with the penultimate aspartic acid and the C-terminal amide of cholecystokinin. Gigoux V; Escrieut C; Fehrentz JA; Poirot S; Maigret B; Moroder L; Gully D; Martinez J; Vaysse N; Fourmy D J Biol Chem; 1999 Jul; 274(29):20457-64. PubMed ID: 10400673 [TBL] [Abstract][Full Text] [Related]
37. [3H]pBC 264, a suitable probe for studying cholecystokinin-B receptors: binding characteristics in rodent brains and comparison with [3H]SNF 8702. Durieux C; Ruiz-Gayo M; Corringer PJ; Bergeron F; Ducos B; Roques BP Mol Pharmacol; 1992 Jun; 41(6):1089-95. PubMed ID: 1614411 [TBL] [Abstract][Full Text] [Related]